[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371310-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371310-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","improved-survival-with-elevated-bmi-following-immune-checkpoint-inhibition-across-various-solid-tumor-cancer-types","Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types","","Obesity is a recognized risk factor for multiple cancers, yet research suggests an “obesity paradox” with improved survival after cancer treatment. This study evaluates whether obesity correlates with better overall survival following immune checkpoint inhibition (ICI) across diverse solid tumor types. TriNetX data (2012–2024) identifies solid-tumor patients receiving ICI and uses propensity score matching for demographics, comorbidities, and staging. Across pan-cancer analysis and multiple organ-system subgroups, obese BMI is linked to significantly improved 5-year overall survival versus normal BMI.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/improved-survival-with-elevated-bmi-following-immune-checkpoint-inhibition-across-various-solid-tumor-cancer-types/371310/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/improved-survival-with-elevated-bmi-following-immune-checkpoint-inhibition-across-various-solid-tumor-cancer-types/371310.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the obesity paradox in the context of cancer and ICI treatment?","Question",{"text":63,"@type":64},"The obesity paradox refers to observations that patients with obesity may experience improved outcomes with oncologic treatment. Here, it is discussed as a potentially underinvestigated factor for patients receiving immune checkpoint inhibition (ICI).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study compare obese vs normal BMI patients after ICI?",{"text":68,"@type":64},"The study queried TriNetX to identify solid-tumor patients treated with ICI between 2012 and 2024. Propensity score matching balanced demographics, medical comorbidities, and oncologic staging, and overall survival up to 5 years was compared between BMI >30 and BMI 20–24.9 cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about overall survival up to 5 years?",{"text":72,"@type":64},"After matching, 18,434 patients were included in the pan-cancer analysis with equal cohort sizes. Obese BMI was associated with significantly improved overall survival up to 5 years versus normal BMI, with hazard ratios below 1 across multiple organ-system subgroups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371310,1790217842,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10. 1002/cncr.35799  \nORIGINAL ARTICLE  \nImproved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types  \nEric V. Mastrolonardo MD 1 | Pablo Llerena BS1  | Emma De Ravin MD1 | Kathryn Nunes BA1 | Praneet C. Kaki BS1 | Kelly M. Bridgham MD 1 | Dev R. Amin MD 1 | Daniel J. Campbell MD 1 | Ramez Philips MD2  |  \nScott H. Koeneman PhD3 | David M. Cognetti MD 1,4 | Adam J. Luginbuhl MD 1,4 | Nicole L. Simone MD5 | Jennifer M. Johnson MD1,4,6 | Joseph M. Curry MD 1,4  \n1Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University  \nHospital, Philadelphia, PA, USA 2Department of Otolaryngology – Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA  \n3Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA, USA  \n4Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA  \n5Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA  \n6Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA  \nCorrespondence  \nJoseph M. Curry, Thomas Jefferson University Hospital, 925 Chestnut St. 6th Floor, Philadelphia PA 19107, USA.  \nEmail: [joseph.curry@jefferson.edu](joseph.curry@jefferson.edu)  \nAbstract  \nIntroduction/Background: Obesity is a well-known risk factor for various cancers, yet emerging research demonstrates its association with improved survival outcomes in cancer treatment, labeled as “the obesity paradox.” Studies investigating the clinical benefits of obesity across various cancer types after immune checkpoint inhibition (ICI) are limited.  \nMethods: Data were queried from the TriNetX database to identify patients with solid tumor malignancies of various organ systems (pulmonary/intrathoracic, cutaneous, head and neck, gastrointestinal, breast, genitourinary) who received ICI between 2012 and 2024. Propensity score matching was used to match cohorts for demographics, medical comorbidities, and oncologic staging. Primary outcome was overall survival (OS) up to 5 years and compared between obese body mass index (BMI; >30) and normal BMI (20–24. 9) cohorts.  \nResults: After propensity score matching, there were a total of 18,434 patients, with 9217 patients in the obese BMI cohort and 9217 patients in the normal BMI cohort for all solid tumor malignancies. In the overall pan-cancer analysis, obese BMI was associated with significantly improved OS up to 5 years compared to the normal BMI cohort (hazard ratio [HR], 0.69 [0.66–0. 72]). Subgroup analysis likewise demonstrated that obese BMI was associated with significantly improved OS up to 5 years for respiratory/intrathoracic (HR, 0.77 [0.72–0.83]), cutaneous (HR, 0.62 [0.63–0. 78]), head and neck (HR, 0.67 [0.58–0. 78]), gastrointestinal (HR, 0.67 [0.58– 0. 78]), breast (HR, 0.66 [0.55–0. 79]), and genitourinary (HR, 0.57 [0.34–0. 93]) malignancies (though not renal cell carcinoma specifically.)  \nConclusions: Obesity was associated with improved 5-year OS after treatment with ICI across various solid tumor malignancies in this electronic health record–based  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2025 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2025;e35799.  \n[https://doi.org/10.1002/cncr.35799](https://doi.org/10.1002/cncr.35799)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 9  \nbig data study. Further investigation is warranted to understand the mechanism of this association.  \nKEYWORDS  \nobesity, immune checkpoint inhibition, solid tumors, overall survival  \nINTRODUCTION  \nThe advent of T-cell–directed immunotherapies has greatly advanced cancer ","cbCaigW8aOzdiQgQ","https://ap.wps.com/l/cbCaigW8aOzdiQgQ","pdf",756595,"English","# Abstract\n## Introduction/Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods","[{\"question\":\"What is the obesity paradox in the context of cancer and ICI treatment?\",\"answer\":\"The obesity paradox refers to observations that patients with obesity may experience improved outcomes with oncologic treatment. Here, it is discussed as a potentially underinvestigated factor for patients receiving immune checkpoint inhibition (ICI).\"},{\"question\":\"How did the study compare obese vs normal BMI patients after ICI?\",\"answer\":\"The study queried TriNetX to identify solid-tumor patients treated with ICI between 2012 and 2024. Propensity score matching balanced demographics, medical comorbidities, and oncologic staging, and overall survival up to 5 years was compared between BMI \\u003e30 and BMI 20–24.9 cohorts.\"},{\"question\":\"What did the results show about overall survival up to 5 years?\",\"answer\":\"After matching, 18,434 patients were included in the pan-cancer analysis with equal cohort sizes. Obese BMI was associated with significantly improved overall survival up to 5 years versus normal BMI, with hazard ratios below 1 across multiple organ-system subgroups.\"}]","Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types | PDF",1790191769,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75f45700e98d113c28ed2f437f0affae.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d21981e90127992199635f2ebb57a327.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47f67ad40a0757f10d505146f8a4a666.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac6ffec044c1b881729c0b74e225254b.webp",980,1287]